Anvendelse af NKp46 til forebyggelse af type 1-diabetes

Ofer Mandelboim; Angel Porgador; Yaakov Naparstek; Chamutal Gur

Anvendelse af NKp46 til forebyggelse af type 1-diabetes

Ofer Mandelboim (Inventor)
, Angel Porgador (Inventor)
, Yaakov Naparstek (Inventor)
, Chamutal Gur (Inventor)

The Shraga Segal Department of Microbiology and Immunology

Research output: Patent

Abstract

The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.

Original language	English
Patent number	DK2408468T3
IPC	C07K 16/ 28 A I
Priority date	18/03/10
State	Published - 21 Jul 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@misc{df57413e5a7e49a3900a5860ef1f81cf,

title = "Anvendelse af NKp46 til forebyggelse af type 1-diabetes",

abstract = "The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.",

author = "Ofer Mandelboim and Angel Porgador and Yaakov Naparstek and Chamutal Gur",

year = "2014",

month = jul,

day = "21",

language = "English",

type = "Patent",

note = "DK2408468T3; C07K 16/ 28 A I",

}

TY - PAT

T1 - Anvendelse af NKp46 til forebyggelse af type 1-diabetes

AU - Mandelboim, Ofer

AU - Porgador, Angel

AU - Naparstek, Yaakov

AU - Gur, Chamutal

PY - 2014/7/21

Y1 - 2014/7/21

N2 - The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.

AB - The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.

M3 - Patent

M1 - DK2408468T3

ER -

Anvendelse af NKp46 til forebyggelse af type 1-diabetes

Abstract

UN SDGs

Fingerprint

Cite this